Mixed Early Phase III Results With Aldeyra’s First-In-Class Dry Eye Candidate
Aldeyra To Initiate Part 2 Of The Adaptive Phase III Study In 2020
Executive Summary
The first part of Aldeyra’s Phase III RENEW study of the aldehyde trap candidate, reproxalap, shows positive effects on one of two co-primary endpoints and indicates an induction-maintenance dosing regimen should be used in part 2 of the study, expected to start in the first half of next year.